Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05382156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Study acronym: LINC6
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Sep 26, 2024, no change to tracked fieldsv5-v6
  2. Study completion date: Feb 2028 to Aug 2027v4
  3. Trial status: Recruiting to Active, Not Recruitingv3 Show 5 more changesShow less
    • Enrollment target: estimated 100 to confirmed 206
    • Study sites: 30 to 43
    • Primary completion date: Jun 2028 to Jun 2027
    • Study completion date: Feb 2029 to Feb 2028
    • Study description shortened, about 1 word
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 30
    • Start date changed from estimate of Jun 2022 to Jun 13, 2022
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
Trial Details
NCT Number NCT05382156
Lead Sponsor RECORDATI GROUP
Conditions
(from sponsor)		 Endogenous Cushing's Syndrome
Related terms Cushing Syndrome
Enrollment 206 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov